NLS Pharmaceutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	5.9	6.51	5.94	2.2	3.3	2.74
Research & Development	5.91	8.98	5.92	0.1	0.9	0.71
Operating Expenses	11.81	15.48	11.86	2.3	4.2	3.45
Operating Income	-11.81	-15.48	-11.86	-2.3	-4.2	-3.45
Interest Expense / Income	0.15	0.1	0.07	0.23	0.82	1.08
Other Expense / Income	0.22	0.91	0.02	0.33	0.43	0.61
Pretax Income	-12.17	-16.5	-11.95	-2.86	-5.45	-5.15
Net Income	-12.17	-16.5	-11.95	-2.86	-5.45	-5.15
Shares Outstanding (Basic)	38	20	12	7	7	6
Shares Outstanding (Diluted)	38	20	12	7	7	6
Shares Change	93.96%	65.38%	71.00%	1.75%	9.62%	-
EPS (Basic)	-0.32	-0.84	-1.00	-0.41	-0.80	-0.82
EPS (Diluted)	-0.32	-0.84	-1.00	-0.41	-0.80	-0.82
Free Cash Flow	-9.68	-13.88	-14.98	-0.73	-0.19	-2.73
Free Cash Flow Per Share	-0.25	-0.70	-1.26	-0.10	-0.03	-0.44
EBITDA	-12.02	-16.38	-11.87	-2.63	-4.63	-4.06
Depreciation & Amortization	0.01	0.01	0.01	0	0	0
EBIT	-12.03	-16.39	-11.88	-2.63	-4.63	-4.06

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).